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GPs’ mindlines on deprescribing antihypertensives 
in older patients with multimorbidity:
a qualitative study in English general practice
INTRODUCTION
There is robust evidence for the benefits of 
prescribing antihypertensive medication,1–4 
including for the oldest patients.5 
Consequently, official guidelines focus on 
the need to prescribe,6,7 and the Quality and 
Outcomes Framework (QOF; the English 
general practice payment-for-performance 
system) sets GPs clear targets for achieving 
controlled blood pressure in patients 
under their care.8 More recent iterations 
of the QOF have, however, recognised the 
importance of personalised treatment 
approaches for frail older patients with 
multimorbidity.8 GPs are encouraged to 
use clinical judgement when choosing 
to exempt patients from QOF indicator 
targets (measures against which practice 
performance is assessed); this may include 
decisions to reduce rather than continue 
medication, including antihypertensives.9–15
How, though, does such clinical 
judgement develop, and what sources 
do GPs draw on in reaching prescribing 
decisions, especially those that relate 
to stopping or reducing medicines? The 
processes involved in clinical decision-
making have been the focus of much 
research, which highlights the gap between 
the rational, information-driven approach 
of evidence-based guidelines and the 
messy realities of clinical practice on the 
ground.16–19 Gabbay and le May describe the 
development of clinical decision-making in 
GPs using the concept of ‘mindlines’:
‘… collectively reinforced, internalised 
tacit guidelines, which were informed 
by brief reading, but mainly by their 
[doctors’] interactions with each other 
and with opinion leaders, patients, and 
pharmaceutical representatives and by 
other sources of largely tacit knowledge 
that built on their early training and their 
own and their colleagues’ experience.’  20
Thus, GPs’ decision-making, informed in 
part by available evidence and guidance, is 
refined through reference to the outcomes 
of previous decisions, whether their own or 
their colleagues’. Information is negotiated, 
shared, and tested in a community of 
practice on an ongoing basis, with iterative 
development of in-practice knowledge.20,21
Importantly, mindlines develop and 
strengthen continually in response 
to newly emerging evidence, as well as 
the need to act.22 GPs are faced with 
decisions around treatment for frail, 
older, hypertensive patients every day. 
Abstract
Background
Optimal management of hypertension in older 
patients with multimorbidity is a cornerstone 
of primary care practice. Despite emphasis on 
personalised approaches to treatment in older 
patients, there is little guidance on how to achieve 
medication reduction when GPs are concerned 
that possible risks outweigh potential benefits 
of treatment. Mindlines — tacit, internalised 
guidelines developed over time from multiple 
sources — may be of particular importance in 
such situations.
Aim
To explore GPs’ decision-making on deprescribing 
antihypertensives in patients with multimorbidity 
aged ≥80 years, drawing on the concept of 
mindlines.
Design and setting
Qualitative interview study set in English general 
practice.
Method
Thematic analysis of face-to-face interviews with 
a sample of 15 GPs from seven practices in the 
East of England, using a chart-stimulated recall 
approach to explore approaches to treatment 
for older patients with multimorbidity with 
hypertension.
Results
GPs are typically confident making decisions to 
deprescribe antihypertensive medication in older 
patients with multimorbidity when prompted by 
a trigger, such as a fall or adverse drug event. 
GPs are less confident to attempt deprescribing 
in response to generalised concerns about 
polypharmacy, and work hard to make sense of 
multiple sources (including available evidence, 
shared experiential knowledge, and non-clinical 
factors) to guide decision-making. 
Conclusion
In the absence of a clear evidence base on when 
and how to attempt medication reduction in 
response to concerns about polypharmacy, GPs 
develop ‘mindlines’ over time through practice-
based experience. These tacit approaches 
to making complex decisions are critical to 
developing confidence to attempt deprescribing 
and may be strengthened through reflective 
practice.
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Here, they are required to make trade-
offs between evidence-supported benefits 
of antihypertensive treatment and potential 
benefits of deprescribing. Relevant ‘brief 
reading’ includes recommendations on how 
to recognise and action opportunities for 
deprescribing,23–25 and National Institute 
for Health and Care Excellence (NICE) 
guidance on multimorbidity, none of which 
offers advice on reducing specific groups of 
medication, including antihypertensives.26 
These reflect the lack of current evidence 
about the advantages of withdrawing 
antihypertensive medication.5,12,13,27
With little information on the safety 
and efficacy of medication reduction, 
increased interest in deprescribing for 
older patients16,28–34 has had minimal 
impact on clinical practice.30,32,35,36 To date, 
studies have focused on barriers and 
facilitators to deprescribing preventive 
medication.13,15,16,29,30,34,36–41 Questions that 
have received far less attention include: 
what shapes the decision-making of GPs 
at the sharp end in managing hypertension 
in frail older patients; how frameworks of 
knowledge are, individually and collectively, 
being created and maintained in response to 
increased attention towards polypharmacy 
concerns; and how GPs might learn from 
these in developing their own decision-
making in this area.
This qualitative study took place as 
part of the OPtimising Treatment for MIld 
Systolic hypertension in the Elderly trial 
(OPTiMISE), whose goal was to compare 
a strategy of antihypertensive medication 
reduction with usual care for older (aged 
≥80 years) patients with multimorbidity in 
primary care.42 The aim was to explore 
how GPs made decisions about prescribing 
and deprescribing antihypertensives in 




This study was a qualitative study using 
chart-stimulated recall approaches to 
explore GPs’ clinical decision-making 
on treatment for older patients with 
hypertension, set in English general 
practice. With the support of a Clinical 
Research Network, the authors aimed, as 
far as possible, to recruit a mixed sample of 
GPs across the following two criteria: length 
of time qualified (<10 or ≥10 years); and 
practice location (rural, urban, or mixed).
Data collection
The authors conducted semi-structured 
face-to-face interviews with GPs, lasting 
between 20–40 minutes. A chart-stimulated 
recall method was used, which is a case-
based technique used to examine clinical 
decision-making, taking account of 
contextual influences on approaches to 
patient care.17 It has been used in a number 
of GP interview studies, including those 
exploring management of multimorbidity 
and hypertension.18 Interviews followed a 
two-phase approach. GPs were asked to 
reflect on two cases, whom they selected 
from their current patient list according 
to the following criteria: aged ≥80 years; 
controlled blood pressure (systolic blood 
pressure <150 mmHg); and receiving 
≥2 antihypertensive medications and 
whom the GP considers may benefit 
from medication reduction due to existing 
polypharmacy, comorbidity, and frailty.
For each patient, GPs were asked to 
consider their approach to the management 
of their patients’ hypertension; how this 
was balanced with their other medical 
conditions; what had influenced their 
management approach for this case; 
whether additional knowledge would have 
further informed their decision-making; 
and how they would think about stopping 
an antihypertensive medication. The 
interviews concluded with a second, more 
open phase of questioning, asking GPs to 
explain their approach to the management 
How this fits in 
While there is robust evidence for the 
benefits of prescribing antihypertensive 
medication in healthy older patients, 
the balance of probable benefit against 
potential risk is less certain in older 
patients with multimorbidity. An emphasis 
on the importance of clinical judgement 
in prescribing decisions for such patients, 
seen for example in recent revisions to the 
Quality and Outcomes Framework (QOF) to 
support person-centred treatment goals, 
is not yet highlighted in specific guidelines 
on how to attempt medication reduction. In 
this examination of how GPs develop and 
apply their clinical judgement in relation to 
medication reduction in older patients with 
multimorbidity, decisions to deprescribe 
were typically based on clear trigger events 
or direct requests from patients. GPs 
found it far harder to come to a decision to 
deprescribe in response to a generalised 
concern about polypharmacy: here, 
experiential knowledge, accrued over time 
and through multiple sources (mindlines), 
was critical to developing confidence in 
deprescribing in the absence of robust 
medication reduction guidelines. 
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of hypertension in older patients, and 
the circumstances and outcomes of any 
previous decisions to stop antihypertensive 
medication. Sample sufficiency was guided 
by the principles of information power.43
All interviews were conducted by a single, 
non-clinical interviewer, audiorecorded, 
and professionally transcribed. A pilot 
interview took place with one GP to assess 
the feasibility of the topic guide.
Analysis
This study used a thematic analysis 
approach,44 with analysis commencing 
alongside data collection. As interviews 
were conducted, two researchers who 
were trained in qualitative methods read 
the transcripts and iteratively developed 
first- and second-level coding frameworks 
as analysis progressed.45 As thinking 
moved from descriptive to analytical, 
the team drew on existing literature on 
GPs’ attitudes to medication reduction 
and deprescribing, as well as models of 
understanding clinical decision-making 
in conditions of uncertainty, notably the 
concept of mindlines.20,21,46,47 Working with 
transcripts, four researchers trained in 
qualitative methods and general practice 
subsequently discussed data and thematic 
development in three half-day workshops. 
A revised coding framework was developed 
following each workshop. As a part of 
data analysis, the major themes identified 
were discussed at a multidisciplinary day-
long analysis workshop attended by GPs, 
cardiovascular physicians, social scientists, 
and a patient representative. This workshop 
was repeated on completion of data 
collection and analysis, with final reflection 
on, and discussion of, the core findings, 
including the application and relevance 
of the concept of mindlines to the data. 
For example, in developing second-level 
coding frameworks, the team reflected 
on how and where key concepts were 
apparent in the data (such as how multiple 
sources of knowledge appeared to be 
distilled and employed by GPs in managing 
hypertension). Thus, these constructs were 
used as a tool to think about the data, rather 
than in a deductive approach to framework 
development and coding.
RESULTS
This study interviewed 15 GPs from seven 
practices based in the East of England 
between May 2017 and October 2017. Three 
practices were rural, three were mixed, 
and one was urban. List size ranged from 
4000 to 11 500. Four GPs were female and 
11 were male; professional experience 
ranged from 1 month to 26 years (Table 1).
Interviews with GPs illustrated the 
complexity of everyday decisions to 
deprescribe antihypertensive medication 
in patients with multimorbidity who are 
≥80 years old in the absence of specific 
guidance. Although clinical considerations 
(such as presence of adverse drug effects, 
recent falls, or drug interactions) were at 
the forefront of GPs’ concerns, their impact 
on medication reduction decisions was not 
always straightforward. GPs consistently 
highlighted the lack of explicit mechanisms 
for medication reduction, fuelling the 
importance of tacit, experiential, and 
non-clinical considerations in decisions 
concerning medication regimens of older 
patients with multimorbidity. 
Specifically, alongside the absence of 
evidence for deprescribing antihypertensives 
and the concurrent lack of guidelines in this 
area, this study’s analysis identified that 
GPs highlighted pressures to meet imposed 
prescribing targets; expectations of the 
patient’s amenability towards medication 
changes; likely concerns of and ability to 
communicate with the patient’s family and/
or carers; and current resource constraints 
(for example, staff time required for additional 
monitoring). As a result, antihypertensive 
medication reduction was not common 
practice, usually only occurring reactively 
following specific trigger events, such 
as a recent fall. Here, decision pathways 
were clear for most GPs. When asked to 
consider proactive medication reduction to 
address polypharmacy in a patient, the 
most reasonable action was less clear. A 
Table 1. Summary details of practices and participants in GP 
interview study
  Patient list GPs Age range,   Range of years at 
Practice ID Area size, n interviewed, n years Sex practice, years
Practice 1 rural 8000 4 30–35 male <5
    45–50 male 5–10
    45–50 male 10–15
    50–55 male 20–25 
Practice 2 mixed 9000 1 50–55 male 5–10 
Practice 3 mixed 9500 2 50–55 female 25–30
    55–60 male 10–15 
Practice 4 urban 11 500 2 30–35 male <5
    35–40 female 5–10
Practice 5 mixed 9500 1 40–45 male 5–10
Practice 6 rural 7000 3 30–35 male <5
    45–50 male 10–15 
    45–50 female 10–15 
Practice 7 rural 4000 2 55–60 male <5 
    55–60 female 5–10
e500  British Journal of General Practice, July 2021
greater readiness to consider medication 
reduction in these circumstances was 
apparent in GPs with more experience, 
and, consequently, more established 
mindlines developed over their years in 
practice. Influences on antihypertensive 
prescribing and deprescribing decisions, 
and the development of polypharmacy 
and medication reduction mindlines, are 
given in Figures 1 and 2. The complexity 
of these practices are discussed in more 
detail below.
Established practices in medication 
decision-making
GPs outlined a number of scenarios in which 
decisions to reduce or remove medication — 
or to continue it — were often straightforward 
to make. In the case of deprescribing, GPs 
were more likely to consider, and were 
more confident about, withdrawing an 
antihypertensive drug if patients reported a 
side effect of such medication (for example, 
dizziness or swollen ankles) or if they were 
concerned about what they referred to as 
‘pill burden’, or had a recent history of 
falls. Additionally, GPs were more likely 
to consider deprescribing antihypertensive 
medications with complicated side effect 
profiles, perceived procurement difficulties, 
or that were absent in updates of the NICE 
guidelines. However, antihypertensives 
were not necessarily the ‘go-to’ choice for 
deprescribing in cases of polypharmacy, 
where other medications might be 
withdrawn first:
‘If people say: “I’m taking too many 
tablets”, then I would look at them and 
see which ones I could cut out. But the 
antihypertensives wouldn’t be at the top 
of that particular list, they would be the 
ones I would hang on to, and I would try 
and cut out other ones first. If someone is 
on a small dose of amitriptyline, because 
they have perhaps had a bit of neuropathic 
pain and the condition is minor, it has 
a side effect profile that’s anticholinergic, 
and for the elderly you try and reduce 
the cholinergic load. So I would be more 
inclined to stop something like that than 
to stop their lisinopril, for example.’ (GP12, 
12 years of experience)
In the case of reviewing medication 
regimens, absence of trigger events or 
adverse effects usually resulted in continued 
polypharmacy:
‘We tend not to actively stop them unless 
[patients] have symptoms. If it ain’t broke, 
why fix it?’ (GP08, 14 years of experience)
Scarcity of explicit sources of knowledge 
and guidance in medication reduction 
decision-making
GPs attempting to consider deprescribing 
were aware of the increased interest 
in reducing polypharmacy, but also 
encountered a wide range of specific 
arguments against medication reduction. 
The majority of GPs interviewed said that 
Figure 1. Influences on antihypertensive prescribing 
and deprescribing decisions for primary care patients. 





























































































Figure 2. Polypharmacy and medication reduction 
mindlines.
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the lack of guidelines was a major barrier to 
deprescribing antihypertensive medication 
in older patients who were not experiencing 
obvious side effects or other complications. 
An absence of guidelines on managing 
hypertension in the context of comorbidity, 
and the multiplicity of single-condition 
guidelines, added to the difficulty of making 
deprescribing decisions:
‘I’d say the guidance is useful for starting 
antihypertensives, [but] there’s little guidance 
about withdrawing them and there’s never 
been any guidance as to timeframes and how 
quickly you should be up-titrating or down-
titrating.’ (GP04, 3 years of experience)
Prescribing decisions were made with an 
eye to requirements set out within the QOF.48 
While GPs appreciated the option to make the 
right decision for the patient, facilitated by the 
possibility of making an exception report from 
the QOF for such patients where necessary 
(currently referred to as a ‘Personalised Care 
Adjustment’),8 they were also wary of the 
burden of additional regulatory inspections if 
targets were not met:
‘We’re a bit reluctant to exempt because 
they think we’re cheating. And if you exempt 
too many people then you get an inspection 
and then we’re all sort of looking over our 
shoulder about this. So, that’s very difficult 
because the system, which is meant to be 
helping people, is actually harming people at 
that point.’ (GP15, 6 months of experience)
This study found that GPs with more 
professional experience appeared more 
likely to deviate from national guidelines 
on acceptable blood pressure levels 
in patients aged ≥80 years and were 
better equipped to draw on their tacit 
knowledge about how to deprescribe. Less 
experienced GPs appeared more likely to 
continue polypharmacy in patients without 
new clinical symptoms, justifying their 
reluctance to deprescribe by the lack of 
explicit evidence of benefit on deprescribing:
‘There are obviously targets to be met for 
people with diabetes in terms of blood 
pressure and things like that, but equally, I’m 
allowed to, where it’s clinically appropriate, 
exceptionalise people anyway, so I can think 
and make that decision.’ (GP10, 10 years of 
experience)
‘Is [the patient] going to have an increased 
risk of heart attacks or strokes from 
stopping [antihypertensives], at this age 
group? Probably not, but can I be a hundred 
per cent certain that she isn’t going to go 
and have a heart attack or stroke? No.’ 
(GP01, 1.5 years of experience)
Patient considerations in medication 
reduction decision-making
Despite the scarcity of explicit guidance on 
deprescribing, some GPs were still willing 
to consider reducing medication regimens 
in people taking multiple medications, while 
acknowledging how complicated these 
decisions could be. Notably, such GPs tended 
to have more years in practice. In considering 
the rationale for medication reduction, GPs 
referred to the importance of a patient’s 
medical history and comorbidities, notably 
renal function, diabetes, and/or previous 
history of strokes or cardiac events:
‘You’ve got to walk the tightrope between not 
upsetting somebody’s kidney function, but 
actually getting their blood pressure under 
control, and then not allowing the heart failure 
to get a hold, and then, if the heart failure gets 
a hold and you end up using diuretics, then 
you upset the diabetes, and they all interact.’ 
(GP11, 26 years of experience)
Concurrently, a number of GPs 
mentioned that some patients, especially 
those with prior experiences of stroke or 
cardiac events, might experience anxiety 
at the prospect of stopping medication that 
lowers the risk of those events. Given that 
common understanding of having a chronic 
condition includes taking medication for 
the rest of one’s life,37,49 GPs with longer 
professional relationships with their 
patients might experience less resistance 
when suggesting medication withdrawal. 
However, this was not always the rule:
‘I think sometimes people are absolutely 
delighted at the prospect of not having to 
take quite so many tablets and actually 
quite welcome it. But people who have had 
a stroke in the past are worried about the 
possibility of having a stroke if you stop the 
antihypertensive. So, I think the way round 
that is to actually talk to people properly 
about the risks and the benefits.’ (GP11, 
26 years of experience)
Conversely, a poorly established 
relationship with a patient made it 
more difficult to bring up the possibility 
of withdrawing medication, as GPs were 
unsure of the patient’s preferences and did 
not want to cause them any unnecessary 
anxiety. As a result, in the absence of 
new medication-related symptoms, 
polypharmacy was likely to be continued:
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‘ [The patient]’s new to the surgery, I don’t 
know him, I don’t know how he feels really 
about the tablets given that I didn’t start them 
myself. It might be his choice that he would 
like to continue taking those tablets as he’s 
been taking them for a while and not had any 
problems.’ (GP01, 1.5 years of experience)
GPs also expressed a concern that older 
patients frequently struggle with adhering 
to their existing medication regimens, 
which meant that any changes — including 
withdrawal of medication — might require 
considerations beyond the clinical effects of 
removing a single drug.
Additionally, GPs recognised that even if 
withdrawal of antihypertensives seemed fairly 
safe from a clinical point of view, the possibility 
of a catastrophic event could not be entirely 
eliminated given the combination of a patient’s 
age and level of multimorbidity. This means 
that even experienced GPs might hesitate 
before making deprescribing decisions:
‘Something’s happened, and then if you say: 
“He’s had a fall and his blood pressure’s low, 
I think we need to reduce the medication”. 
That’s a lot easier than the more subtle quality 
of life, you know, potential risk of side-effect. 
And moving on, I guess your own worry as a 
GP is that if you do stop his anti-hypertensives, 
if he has a stroke 2 weeks later, whether it 
be incidental or not, is that your fault or not?’ 
(GP10, 10 years of experience)
Some GPs mentioned that they found 
themselves in a difficult position when their 
patients received specialist advice that 
was in conflict with more holistic primary 
care goals. Resolving these conflicts can 
undermine the patient’s trust, especially if 
the specialist’s recommendations cannot be 
easily integrated with patient’s preferences or 
priorities, and the GP’s perceptions of these:
‘To be quite blunt, I am getting tired of my 
elderly, frail patients being discharged 
[from hospitals] on long-term preventative 
medication that is potentially harmful. I think 
[consultants] need to be thinking about what 
they’re discharging on; sometimes these 
polypharmacy patients could have a fall and 
end up in hospital. I would appreciate those 
doctors to be reviewing the polypharmacy, 
to be assisting us in this. It can’t just come 
from general practice.’ (GP15, 6 months of 
experience)
Additional sources of concern in 
medication reduction decision-making
Complex considerations impacting 
decisions to deprescribe also involved 
factors beyond the health conditions of 
individual patients. For instance, almost all 
GPs interviewed mentioned that family and 
carers must be taken into account when 
considering medication changes for older 
patients. There was a general recognition 
that decisions about medical care stretch 
beyond the doctor–patient dyad, irrespective 
of the patient’s ability to make independent 
choices:
‘If [the patient’s] family were a little bit more, 
sort of, accepting that age doesn’t mean 
that you’ve got to take lots of medication. 
And if they were less demanding on health 
services to expect that we continue to do 
things, and that if you stop something 
it doesn’t mean that you’re being a bad 
doctor, it means you’re just really trying to 
improve the quality of life index rather than 
pill pushing.’ (GP02, 15 years of experience)
Many GPs pointed to additional time 
and resources necessary to monitor a safe 
withdrawal of antihypertensives that had 
to be weighed against the possibility of 
an adverse event, or even litigation. This 
included the potential for additional or 
longer appointments, home monitoring 
of blood pressure, and home visits for 
housebound patients. This was one of 
the main reasons for doctors being less 
keen on changing medication regimens in 
patients with no specific antihypertensive-
related side effects:
‘Is there anything that’s stopping me, other 
than the problem that it could take more 
time, it could take more appointments 
to facilitate a safe withdrawal of tablets, 
in terms of following up with repeat 
home blood pressure monitoring, repeat 
appointments as to why we’re going to stop 
them as she’s been taking them for such a 
long time and been fine with them.’ (GP01, 
1.5 years of experience)
DISCUSSION
Summary
In older patients with multimorbidity, 
deprescribing decisions relating to 
antihypertensives are not straightforward. 
In everyday clinical practice, prescribing and 
deprescribing decisions demand GPs trade 
off a variety of factors, including explicit 
pressures of prescribing targets, tacit and 
practical knowledge on polypharmacy 
appropriateness for individual patients, 
patient preferences, and even concerns 
from families wanting more active 
medical care for their loved ones. In cases 
where there are clear trigger events for 
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deprescribing (such as specific symptoms, 
a fall, or an explicit request from the 
patient), mindlines are well established. 
Outside of such triggers, this study shows 
that mindlines lead to a cautious approach 
to deprescribing by GPs, and a ‘watch-and-
wait’ approach is prevalent. Consequently, 
even those GPs who would be keen to 
reduce polypharmacy in their older patients 
with multimorbidity may find it difficult 
to justify withdrawing antihypertensives 
without an explicit clinical reason, even in 
the context of strong relational continuity.
Deprescribing outside of a trigger event 
was considered more frequently by GPs 
whose mindlines were informed by many 
more years of clinical experience. Newly 
qualified GPs were less confident about 
stopping preventive medication in patients 
with complicated regimens who were not 
experiencing side effects or another active 
clinical concern. The climate in which GPs 
practice makes them acutely aware of the 
threat of litigation following a deprescribing 
decision that led to an adverse event, 
making them less willing to consider 
medication reduction. Although GPs’ 
anxiety about stopping antihypertensives 
is likely to decrease as they gain more 
professional experience, their mindlines 
may form more readily if specific guidelines 
on reducing polypharmacy were available. 
Such guidelines will not become available 
without first generating robust empirical 
data from trials and (to a lesser extent) 
observational studies. 
Strengths and limitations
While this study fits in with other 
research focusing on barriers and 
facilitators to deprescribing preventive 
medication,13,15,16,29,30,33,34,36–41 it focuses 
on gaps in GPs’ in-practice knowledge 
and practice related to deprescribing 
antihypertensives, drawing on thinking 
around mindlines. Within the interview 
study, the use of chart-stimulated recall 
can add to the specificity of interview 
data and facilitate deeper reflection 
in participants.50 GPs were asked to 
hypothesise about deprescribing decisions 
in cases of specific patients, which required 
real-time articulation of reasons about why 
deprescribing did not occur. The findings 
of the study may be limited by the small 
geographical area in England from which 
GPs were recruited and by the relatively low 
number of participants.
Comparison with existing literature
Clinicians develop mindlines through 
everyday clinical practice and interaction. 
The robustness of these mindlines depends 
on available information in the form of 
the clinical evidence base (and guidelines) 
as well as professional experience and 
informal knowledge exchange between 
peers. Participating GPs in this study’s 
sample have demonstrated how their 
decision-making about deprescribing 
draws primarily on their own and their 
colleagues’ professional experience.20 
Where the evidence base on the need to 
deprescribe was perceived to be clearer, 
such as in response to a trigger event, GPs’ 
mindlines were well developed. In other 
scenarios, however, mindlines tended to 
emerge more readily only among those 
physicians who have been practising longer. 
Evidence supports the significance of 
mindlines in understanding how clinical 
decisions are made in the context of 
individual patients’ circumstances and 
broader structural pressures.21,29,51 
A recent example of the nature and 
impact of mindlines comes from a study 
of management strategies for atopic 
eczema.51 Despite available evidence, such 
as NICE guidelines and local emollient 
guidelines, providing evidence-based 
treatment was challenging for GPs, who 
often perceived changes to recommended 
emollients as economically motivated. 
Instead, GPs’ mindlines drew on their 
own and their colleagues’ experience 
of managing eczema as well as online 
resources. Interestingly, practitioners who 
had personal experience of eczema were 
also the most likely to articulate a nuanced 
understanding of eczema management, 
including robust knowledge of available 
products to treat it.51
A growing interest in deprescribing in 
older patients with multimorbidity has 
been fuelled by mounting evidence on the 
potential harms of polypharmacy over the 
last two decades,11–14,27 as evidenced by the 
changes in the QOF.8 However, these trends 
have yet to translate into specific guidelines 
that would equip GPs for stopping preventive 
medication with the degree of confidence 
with which they prescribe it.17,31 In this context, 
GPs must (and do) rely on their own and 
their colleagues’ experience when making 
decisions to deprescribe. Consequently, 
the decision to continue polypharmacy 
in a patient who is not experiencing any 
side effects may often simply seem both 
risk-averse and wise, as exemplified in this 
study’s interviews with GPs.
Implications for research and practice
There is a rising need to secure evidence 
on when and for whom deprescribing is 
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most likely to be beneficial, as current 
practice heavily relies on GPs' experience 
and intuition. These tacit approaches to 
making complex decisions are critical 
to developing confidence to attempt 
deprescribing and may be strengthened 
through reflective practice. As future 
doctors will be dealing with an increasingly 
aged cohort of patients with multimorbidity, 
deprescribing as a skill will need a place 
in the medical training curriculum. At the 
same time, it is important to recognise that, 
given the complexity of individual people 
taking multiple medications, professional 
guidelines and training are unlikely to be 
sufficient to address each patient’s needs 
and preferences in the light of their complex 
medication regimens and possible adverse 
effects. Doctors will develop and rely on 
mindlines when making complex decisions 
about reducing polypharmacy: surfacing the 
nature of such mindlines — as in this study 
— is one way to share practice more widely. 
As time goes on, an improved evidence 
base on the impact of deprescribing and 
guidelines on when and how to deprescribe 
are likely to support the strengthening 
of mindlines around deprescribing, even 
without trigger events.
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